The Medicaid expansion under the Patient Protection and Affordable Care Act resulted in a 19% annual increase in Medicaid-insured cancer patients participating in publicly funded clinical trials, according to researchers from Fred Hutchinson Cancer Center, the SWOG Statistics and Data Management Center and Columbia University.
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those surgeries, but still opt for lower volume hospitals closer to home when their cancer is likely less complex, according to an analysis by health policy scientists at the University of Pittsburgh School of Public Health.
The phase III ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met its primary endpoint of disease-free survival at a prespecified interim analysis.
In a prespecified interim analysis of the phase III LITESPARK-005 trial, Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Afinitor (everolimus) in adult patients with advanced renal cell carcinoma that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor therapies.
Robotic technology available at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is enabling physicians to obtain tissue biopsies in previously hard-to-reach areas of the lung to test for cancer.
Rural women with cancer often receive financial support from within their communities and from formal organizations, but not all patients have equal access to this assistance, according to a study conducted by researchers at the University of Arkansas for Medical Sciences Office of Community Health & Research.
A “weighted” lottery program designed to ensure that people living in the most disadvantaged U.S. neighborhoods would be offered a scarce, potentially life-saving medication proved feasible in a large health system. The approach can improve equity in receipt of the drug by people disproportionately affected by disease, according to an analysis published today in JAMA Health Forum by University of Pittsburgh and UPMC scientist-clinicians.
Scientists at City of Hope have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases.
Researchers at MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a phase I clinical trial.
A team of University of Florida medicinal chemists and cancer biologists has created a chemical compound that selectively helps cells dispose of proteins that cause cancer cells to grow.
